Gabelli Funds’s Aimmune Therapeutics AIMT Stock Holding History

Gabelli Funds’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,131,979	Closed	-$39M	–	1280
2020 Q3	$39M	Buy	+1,131,979	New	+$24.1M	0.3%	92

Gabelli Funds's AIMT Position: Q4 2020 in Review

Gabelli Funds sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 1,131,979 shares — an estimated $39M sold.

Gabelli Funds first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $39M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Gabelli Funds reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Gabelli Funds sold 1,131,979 Aimmune Therapeutics shares in Q4 2020, an estimated $39M.
Gabelli Funds first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Gabelli Funds's Aimmune Therapeutics position peaked at $39M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Gabelli Funds's 13F filing for Q4 2020, filed 5 Feb 2021.